Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05546086

BeijngFH Health Cohort Study

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-Alcoholic Fatty Liver Disease Digestive System Diseases Fatty Liver Liver Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The present community-based cohort study enrolls subjects who take physical health examinations at the sub-center outpatient department, Beijing Friendship Hospital. After signing the informed consent, Their previous health physical examination results, which were recorded in the Hospital Information System (HIS) are collected retrospectively. Then, Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, image logical examination, and so on. Additionally, follow-up surveys will be conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, is obtained from the hospital discharge database and death registration system in Beijing. The study's primary aim is to build a risk-stratified evaluation system for MAFLD through a community population cohort with long-term stable follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years or older
  • Permanent residents in Beijing
  • Signing informed consent

Exclusion criteria

  • No

Treatment and study plan

Primary outcomes

  1. Cardiovascular disease

    Time frame: 1 to 10 years

    Incidence of cardiovascular disease during follow-ups

Secondary outcomes

  1. Malignancy

    Time frame: 1 to 10 years

    Incidence of malignancy during follow-ups

  2. Liver cirrhosis

    Time frame: 1 to 10 years

    Incidence of liver cirrhosis during follow-ups

  3. Liver decompensation

    Time frame: 1 to 10 years

    Incidence of liver decompensation during follow-ups

  4. Liver transplantation

    Time frame: 1 to 10 years

    Incidence of liver transplantation during follow-ups

  5. All-cause mortality

    Time frame: 1 to 10 years

    Incidence of all-cause mortality during follow-ups

Study contacts

Contact information is provided by the study sponsor or research team.

Hong You, Doctor

CONTACT

[email protected]

86-010-63139019

Xinyu Zhao, Doctor

CONTACT

[email protected]

86-010-63139364

Sponsors and collaborators

Lead sponsor

Beijing Friendship Hospital

Other

Collaborators

  • Chinese Academy of Medical Sciences

Registry information

Official study title

Risk Prediction System for Metabolic Associated Fatty Liver Disease, a Community-based Cohort Study

Acronym: FHCS

Important dates

Study start
2022
Primary completion
2032
Study completion
2032
First posted
Sep 19, 2022
Registry last updated
Sep 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.